Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Therapeutic Agent Characterization and Preclinical Efficacy Studies
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for early-stage biomedical and behavioral research organizations seeking to develop novel therapeutic agents or characterize existing compounds. Eligible applicants include academic institutions, research organizations, small businesses, and nonprofits with NIH 501(c)(3) status or equivalent. Projects must focus on therapeutic characterization, preclinical efficacy studies, or translation of laboratory findings toward clinical application. Funding supports proof-of-concept work to advance candidates from basic science toward therapeutic development.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Feb 25, 2026 Applications open
- Sep 30, 2026 Application deadline in 76 days
- Jul 1, 2027 Award announced
- Jul 1, 2027 Project start
Program description
The National Institute of Neurological Disorders and Stroke, National Institute of Aging, the NIH Helping to End Addiction Long Term (HEAL) initiative, and other participating ICs seek to support applications to conduct pharmacodynamic, pharmacokinetic, and efficacy studies to demonstrate that the proposed therapeutic agent(s) have sufficient biological activity to warrant further development as therapeutics for disorders or diseases supported by participating ICs or for non-opioid analgesic therapeutics with little or no addiction liability as a part of the NIH HEAL initiative. Therapeutic agents include small molecules or biologics. Efficacy testing can be conducted in validated in vivo models and/or validated New Approach Methodologies (NAMs) as appropriate.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Application for Federal Assistance)
- Project Narrative
- Budget and Budget Justification
- Biosketch (Key Personnel)
- Institutional Support Letter
- Letters of Commitment (if applicable)
Program contact
- 👤 NINDS_IGNITE@nih.gov
- 📧 NINDS_IGNITE@nih.gov
- 📞 Please contact via email
Funding track record
Recent awards under CFDA 93.853 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$56,144,651
-
$40,959,789
-
$35,655,349
-
$35,655,116
-
$35,335,145
-
$34,183,297
-
$32,294,153
-
$32,234,840
-
$31,739,294
-
$27,282,286
Top States by Funding
- MA 5 awards $123.9M
- OH 4 awards $112.5M
- CA 4 awards $101.3M
- FL 3 awards $100.3M
- MI 3 awards $85.3M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.853). How funding has trended year over year.
| 2024 | $2,362,835,459 | |
| 2025 | $2,345,500,401 |
FAQ
Who can apply for this NIH IGNITE grant?
Academic institutions, research centers, small businesses, nonprofits, and other organizations with institutional capacity. Individual researchers or unaffiliated researchers cannot apply directly.
What types of projects does this grant support?
Therapeutic agent characterization, preclinical efficacy studies, and translation work. Projects bridge basic science to early drug development stages.
How much funding is typically available?
NIH IGNITE grants typically provide $50,000-$300,000 per award. Check the full RFP for exact funding ranges.
What documents do I need to submit?
SF-424 form, project narrative, budget justification, biosketch for key personnel, and institutional support letter are standard.
How competitive is this program?
Moderate to moderately high. Success requires clear translational goals and preliminary data supporting feasibility.
💡 Tips for applicants
- Start with strong preliminary data showing feasibility of your therapeutic approach or agent characterization plan.
- Clearly articulate the translational pathway from your preclinical work toward clinical application or next-stage development.
- Identify potential commercial or clinical partners early to demonstrate real-world relevance and pathway to impact.
- Budget for rigorous preclinical work: animal studies, assays, characterization data, and technical validation require substantial resources.
- Submit well in advance of the deadline to allow time for institutional approvals and internal review.
⚠️ Common mistakes
Lack of preliminary data showing feasibility. Applications without clear translation potential or clinical relevance struggle. Underestimating budget and timeline for rigorous preclinical validation work.
Similar grants
- OPEN Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification — National Institutes of Health
- OPEN Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) — National Institutes of Health